These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
108 related articles for article (PubMed ID: 21103860)
21. The metabolism and transplacental transfer of oseltamivir in the ex vivo human model. Worley KC; Roberts SW; Bawdon RE Infect Dis Obstet Gynecol; 2008; 2008():927574. PubMed ID: 18551180 [TBL] [Abstract][Full Text] [Related]
22. Oseltamivir for prophylaxis of influenza in vaccinated hemodialysis patients. Van Praet JT; Steyaert S; Demesmaecker M; Grootaert V; Reynders M Infect Control Hosp Epidemiol; 2019 Apr; 40(4):497-498. PubMed ID: 30767820 [No Abstract] [Full Text] [Related]
23. Biodistribution and metabolism of the anti-influenza drug [11C]oseltamivir and its active metabolite [11C]Ro 64-0802 in mice. Hatori A; Arai T; Yanamoto K; Yamasaki T; Kawamura K; Yui J; Konno F; Nakao R; Suzuki K; Zhang MR Nucl Med Biol; 2009 Jan; 36(1):47-55. PubMed ID: 19181268 [TBL] [Abstract][Full Text] [Related]
24. Absence of pharmacokinetic interaction between intravenous peramivir and oral oseltamivir or rimantadine in humans. Atiee G; Lasseter K; Baughman S; McCullough A; Collis P; Hollister A; Hernandez J J Clin Pharmacol; 2012 Sep; 52(9):1410-9. PubMed ID: 21960669 [TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics of the Monoclonal Antibody MHAA4549A Administered in Combination With Oseltamivir in Patients Hospitalized With Severe Influenza A Infection. Deng R; She G; Maia M; Lim JJ; Peck MC; McBride JM; Kulkarni P; Horn P; Castro A; Newton E; Tavel JA; Hanley WD J Clin Pharmacol; 2020 Nov; 60(11):1509-1518. PubMed ID: 32621543 [TBL] [Abstract][Full Text] [Related]
26. H1N1 influenza in pregnancy: cause for concern. Spradlin TL; Clardy BH; Payne EM; Vinson J Obstet Gynecol; 2010 Jan; 115(1):185. PubMed ID: 20027058 [No Abstract] [Full Text] [Related]
27. Comparison of anti-influenza virus activity and pharmacokinetics of oseltamivir free base and oseltamivir phosphate. Shin JS; Ku KB; Jang Y; Yoon YS; Shin D; Kwon OS; Go YY; Kim SS; Bae MA; Kim M J Microbiol; 2017 Dec; 55(12):979-983. PubMed ID: 29214495 [TBL] [Abstract][Full Text] [Related]
28. Effects of dexamethasone coadministered with oseltamivir on the pharmacokinetics of oseltamivir in healthy volunteers. Jang K; Kim MK; Oh J; Lee S; Cho JY; Yu KS; Choi TK; Lee SH; Lim KS Drug Des Devel Ther; 2017; 11():705-711. PubMed ID: 28331290 [TBL] [Abstract][Full Text] [Related]
29. Oseltamivir dose adjustment in an H1N1 patient requiring haemodialysis. Dolley-Hitze T; Verdier MC; Tribut O; Le Tulzo Y; Marqué S Intensive Care Med; 2010 Sep; 36(9):1618-9. PubMed ID: 20625883 [No Abstract] [Full Text] [Related]
30. Carboxylesterase 1 polymorphism impairs oseltamivir bioactivation in humans. Tarkiainen EK; Backman JT; Neuvonen M; Neuvonen PJ; Schwab M; Niemi M Clin Pharmacol Ther; 2012 Jul; 92(1):68-71. PubMed ID: 22588607 [TBL] [Abstract][Full Text] [Related]
31. A part-randomized study of intravenous oseltamivir in adolescents and adults. Várkonyi I; Chappey C; Giraudon M; Burleigh L Eur J Clin Microbiol Infect Dis; 2015 Jun; 34(6):1181-8. PubMed ID: 25678009 [TBL] [Abstract][Full Text] [Related]
32. Association of Oseltamivir Activation with Gender and Carboxylesterase 1 Genetic Polymorphisms. Shi J; Wang X; Eyler RF; Liang Y; Liu L; Mueller BA; Zhu HJ Basic Clin Pharmacol Toxicol; 2016 Dec; 119(6):555-561. PubMed ID: 27228223 [TBL] [Abstract][Full Text] [Related]
33. Developmental changes of brain distribution and localization of oseltamivir and its active metabolite Ro 64-0802 in rats. Morimoto K; Nagami T; Matsumoto N; Wada S; Kano T; Kakinuma C; Ogihara T J Toxicol Sci; 2012; 37(6):1217-23. PubMed ID: 23208436 [TBL] [Abstract][Full Text] [Related]
34. A prospective intervention study on higher-dose oseltamivir treatment in adults hospitalized with influenza a and B infections. Lee N; Hui DS; Zuo Z; Ngai KL; Lui GC; Wo SK; Tam WW; Chan MC; Wong BC; Wong RY; Choi KW; Sin WW; Lee EL; Tomlinson B; Hayden FG; Chan PK Clin Infect Dis; 2013 Dec; 57(11):1511-9. PubMed ID: 24046309 [TBL] [Abstract][Full Text] [Related]
35. The pharmacokinetics and tolerability of oseltamivir suspension in patients on haemodialysis and continuous ambulatory peritoneal dialysis. Robson R; Buttimore A; Lynn K; Brewster M; Ward P Nephrol Dial Transplant; 2006 Sep; 21(9):2556-62. PubMed ID: 16799169 [TBL] [Abstract][Full Text] [Related]
36. Failure of combination oral oseltamivir and inhaled zanamivir antiviral treatment in ventilator- and ECMO-treated critically ill patients with pandemic influenza A (H1N1)v. Petersen E; Keld DB; Ellermann-Eriksen S; Gubbels S; Ilkjær S; Jensen-Fangel S; Lindskov C Scand J Infect Dis; 2011 Jul; 43(6-7):495-503. PubMed ID: 21309638 [TBL] [Abstract][Full Text] [Related]
37. Simulation of the Pharmacokinetics of Oseltamivir and Its Active Metabolite in Normal Populations and Patients with Hepatic Cirrhosis Using Physiologically Based Pharmacokinetic Modeling. Chen Y; Ke M; Xu J; Lin C AAPS PharmSciTech; 2020 Mar; 21(3):98. PubMed ID: 32128656 [TBL] [Abstract][Full Text] [Related]
38. Safety and pharmacokinetics of oseltamivir at standard and high dosages. Dutkowski R; Smith JR; Davies BE Int J Antimicrob Agents; 2010 May; 35(5):461-7. PubMed ID: 20189775 [TBL] [Abstract][Full Text] [Related]
39. Effects of alcohol on human carboxylesterase drug metabolism. Parker RB; Hu ZY; Meibohm B; Laizure SC Clin Pharmacokinet; 2015 Jun; 54(6):627-38. PubMed ID: 25511794 [TBL] [Abstract][Full Text] [Related]
40. The posology of oseltamivir in infants with influenza infection using a population pharmacokinetic approach. Kamal MA; Acosta EP; Kimberlin DW; Gibiansky L; Jester P; Niranjan V; Rath B; Clinch B; Sánchez PJ; Ampofo K; Whitley R; Rayner CR Clin Pharmacol Ther; 2014 Sep; 96(3):380-9. PubMed ID: 24865390 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]